A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients.
Khojasteh
N H
NH
Bone Marrow Transplantation Unit, Nemazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Zakerinia
M
M
Ramzi
M
M
Haghshenas
M
M
D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000517:prevention & control*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D015080:Mesna / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D020011:Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*
D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna